Table 1 Results from a randomized-crossover trial of sodium restriction in hypertensive CKD patients
| Â | Baseline | High sodium | Low sodium |
|---|---|---|---|
Sodium excretion (mmol/24 hr)# | 127 (80–187) | 168 (146–219) | 75 (58–112)* |
Kidney function | Â | Â | Â |
eGFR# (mL/min) | 32 (23–42) | 39 (23–39) | 30 (17–36)* |
Serum creatinine# (μmol/L) | 184 (135–244) | 149 (135–230) | 172 (157–276)* |
Serum urate# (mmol/L) | 0.44 (0.40–0.47) | 0.39 (0.34–0.45) | 0.46 (0.41–0.51)* |
Protein: Creatinine (24 h urine)# (g/mol creat) | 49 (12–97) | 68 (23–164) | 41 (17–126)* |
Albumin: Creatinine (24 h urine)# (g/mol creat) | 21 (2–65) | 27 (5–127) | 9 (2–82)* |
Volume status | Â | Â | Â |
Extracellular/Intracellular fluid ratio | 0.86 ± 0.14 | 0.92 ± 0.14 | 0.87 ± 0.13* |
Overhydration (L)# | −0.6 (−1.6–1.4) | 0.8 (−1.1–2.6) | −0.5 (−1.7–0.9)* |
NT–proBNP (pg/mL)# | NA | 330 (167–793) | 205 (124–528)* |
Inflammatory markers | Â | Â | Â |
C-reactive protein (mg/L)# | 3.3 (1.6–5.8) | 2.8 (1.5–5.5) | 2.7 (1.0–7.3) |
Interleukin-6 (pg/mL)# | NA | 1.9 (1.6–2.8) | 1.9 (1.4–2.8) |
Interferon-gamma (pg/mL)# | NA | 0.8 (0.5–1.1) | 1.0 (0.5–1.4) |
Tumor necrosis factor – alpha (pg/mL)# | NA | 6.8 (5.8–8.7) | 7.3 (5.3–9.0) |
Total adiponectin (ng/L) | 8.1 ± 3.5 | 7.8 ± 3.6 | 8.0 ± 3.7 |
High molecular weight adiponectin (μg/mL) | 5.6 ± 3.1 | 3.9 ± 2.5 | 3.9 ± 2.6 |